...
机译:一中的临床试验评估异丙石的药代动力学,药效动物,安全性和耐受性,一种抗CD40单克隆抗体
Novartis Institutes for BioMedical ResearchBasel Switzerland;
Novartis Institutes for BioMedical Research Inc.Cambridge Massachusetts USA;
Novartis Pharmaceuticals CorporationEast Hanover New Jersey USA;
Novartis Institutes for BioMedical ResearchBasel Switzerland;
Novartis Institutes for BioMedical ResearchBasel Switzerland;
Novartis Institutes for BioMedical ResearchBasel Switzerland;
Novartis Institutes for BioMedical ResearchBasel Switzerland;
Novartis Institutes for BioMedical ResearchBasel Switzerland;
Novartis Institutes for BioMedical ResearchBasel Switzerland;
Novartis Institutes for BioMedical ResearchBasel Switzerland;
Novartis Institutes for BioMedical ResearchBasel Switzerland;
Novartis Institutes for BioMedical ResearchBasel Switzerland;
Novartis Institutes for BioMedical ResearchBasel Switzerland;
Novartis Institutes for BioMedical ResearchBasel Switzerland;
Novartis Institutes for BioMedical ResearchBasel Switzerland;
Novartis Institutes for BioMedical Research Inc.Cambridge Massachusetts USA;
Celerion Inc.Lincoln Nebraska USA;
QPS MiamiSouth Miami Florida USA;
Novartis Institutes for BioMedical ResearchBasel Switzerland;
Novartis Institutes for BioMedical ResearchBasel Switzerland;
clinical research/practice; clinical trial; immunosuppressant – fusion proteins and monoclonal antibodies: B cell specific; immunosuppression/immune modulation; translational research/science;
机译:一中临床试验评估异丙石的药代动力学,药效动物,安全性和耐受性,抗CD40单克隆抗体
机译:Contrail I学习理由和设计:Iscalimab的药代动力学,药效学,疗效和安全性评估(CFZ533) - De Novo肝移植中的抗CD40单克隆抗体
机译:抗CD40单克隆抗体Iscalimab(CFZ533)的疗效,安全,药代动力学和药效学和药效学(CFZ533)在De Novo肝脏移植受者:我学习的轨迹的理由和设计
机译:在健康男性志愿者中单次皮下注射Teverelix储库制剂后的安全性,耐受性,药效动力学和药代动力学
机译:抗蓖麻毒蛋白单克隆抗体的表征和鼠/人IgG2 / K嵌合抗蓖麻毒蛋白单克隆抗体的构建
机译:类癌抑制素M单克隆抗体在类风湿关节炎中的安全性耐受性药代动力学和药效学:II期随机安慰剂对照试验的结果
机译:类癌抑制素M单克隆抗体在类风湿关节炎中的安全性,耐受性,药代动力学和药效学:II期随机,安慰剂对照试验的结果